Allakos Inc. ALLK
We take great care to ensure that the data presented and summarized in this overview for Allakos Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ALLK
View all-
Bvf Inc San Francisco, CA16.6MShares$5.46 Million0.17% of portfolio
-
Tang Capital Management LLC San Diego, CA8.69MShares$2.87 Million0.13% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.23MShares$2.39 Million0.06% of portfolio
-
Nea Management Company, LLC Timonium, MD6.15MShares$2.03 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.43MShares$1.13 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.94MShares$970,1520.0% of portfolio
-
Logos Global Management LP San Francisco, CA2.9MShares$957,0000.13% of portfolio
-
Alta Partners Management Company, L.P. Jackson, WY2.55MShares$840,2281.39% of portfolio
-
Black Rock Inc. New York, NY1.27MShares$418,1520.0% of portfolio
-
Ikarian Capital, LLC Dallas, TX1.17MShares$386,7430.04% of portfolio
Latest Institutional Activity in ALLK
Top Purchases
Top Sells
About ALLK
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
Insider Transactions at ALLK
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 15
2025
|
Bvf Partners L P > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,312,872
-100.0%
|
-
|
|
May 15
2025
|
Paul Edward Walker |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
6,147,260
-100.0%
|
-
|
|
May 15
2025
|
Harlan Baird Radford Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
163,426
-100.0%
|
-
|
|
May 15
2025
|
Adam Tomasi President |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
20,790
-100.0%
|
-
|
|
May 15
2025
|
Adam Tomasi President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
512,630
-100.0%
|
-
|
|
May 15
2025
|
Robert Alexander Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
320,300
-100.0%
|
-
|
|
May 15
2025
|
Robert Alexander Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
738,104
-100.0%
|
-
|
|
Mar 06
2025
|
Robert Alexander Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
31,370
-4.08%
|
$0
$0.26 P/Share
|
|
Mar 05
2025
|
Harlan Baird Radford Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14,161
-7.97%
|
$0
$0.26 P/Share
|
|
Mar 05
2025
|
Adam Tomasi President |
SELL
Payment of exercise price or tax liability
|
Direct |
20,017
-3.76%
|
$0
$0.26 P/Share
|
|
Dec 06
2024
|
Harlan Baird Radford Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,138
-6.89%
|
$13,138
$1.1 P/Share
|
|
Dec 06
2024
|
Adam Tomasi President |
SELL
Payment of exercise price or tax liability
|
Direct |
21,116
-3.81%
|
$21,116
$1.1 P/Share
|
|
Dec 05
2024
|
Robert Alexander Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
32,466
-4.05%
|
$32,466
$1.1 P/Share
|
|
Dec 04
2024
|
Chin Hyok Lee Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,634
-3.72%
|
$10,634
$1.13 P/Share
|
|
Sep 11
2024
|
Robert Alexander Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
37,311
-4.45%
|
$0
$0.58 P/Share
|
|
Sep 09
2024
|
Chin Hyok Lee Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
45,320
-13.69%
|
$0
$0.65 P/Share
|
|
Sep 06
2024
|
Harlan Baird Radford Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,665
-6.69%
|
$0
$0.65 P/Share
|
|
Sep 06
2024
|
Adam Tomasi President |
SELL
Payment of exercise price or tax liability
|
Direct |
21,961
-3.81%
|
$0
$0.65 P/Share
|
|
Jun 28
2024
|
Harlan Baird Radford Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
87,064
-29.87%
|
$87,064
$1.01 P/Share
|
|
Jun 07
2024
|
Adam Tomasi President |
SELL
Payment of exercise price or tax liability
|
Direct |
24,749
-4.14%
|
$24,749
$1.12 P/Share
|
Last 12 Months Summary
| Sale (or disposition) back to the issuer | 24.2M shares |
|---|---|
| Payment of exercise price or tax liability | 261K shares |
| Open market or private sale | 87.1K shares |